MarketCap
Facebook
X
Telegram
Ovid Therapeutics Operating Income | OVID
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Ovid Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.4 M | -61.9 M | -59.3 M | -55.5 M | 124 M | -81.4 M | -61.4 M | -52.9 M | -65 M | -22.5 M | -13.2 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 M | -81.4 M | -35.6 M |
Quarterly Operating Income Ovid Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.4 M | -15.7 M | -17.8 M | -12.3 M | -12.5 M | -5.07 M | -12.6 M | -10.7 M | -13.2 M | -20.5 M | -17.4 M | -18.2 M | -12 M | -14.2 M | -14.9 M | - | -12.8 M | -14.3 M | -16.3 M | -26.4 M | -11.7 M | -14.3 M | 177 M | -21.6 M | -16.4 M | -23.1 M | -20.3 M | -17.3 M | -16.8 M | -13.3 M | -14.1 M | - | -13.2 M | -13.2 M | -13.4 M | - | -9.41 M | -10.3 M | -34.3 M | - | -5.81 M | -5.42 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 177 M | -34.3 M | -10.2 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Windtree Therapeutics
WINT
|
-26.1 M | - | - | $ 26.8 M |  USA |
 |
SQZ Biotechnologies Company
SQZ
|
-80.7 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-66.6 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-8.67 M | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
-31 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | USA |
 |
Generation Bio Co.
GBIO
|
-142 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
-28.9 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-272 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-136 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-216 M | $ 4.2 | -0.36 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
15.1 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-30.2 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
-62.1 M | $ 316.97 | 4.77 % | $ 24.7 B | USA |
|
TFF Pharmaceuticals
TFFP
|
-21.9 M | - | -60.05 % | $ 125 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-68.8 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
-77 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-612 M | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-4.12 M | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
502 M | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
9.08 B | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
-39.8 M | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
-69.5 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
-430 M | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
21.6 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
-39.2 M | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-10.3 M | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
-432 M | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
-36.6 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-46.2 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-153 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
-115 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-43.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
31.3 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-517 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
-21.6 M | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
-31.2 M | - | -33.41 % | $ 3.37 M | USA |